We know viral titer determination is essential for the safe and effective dosing of gene therapy products, but methods used to measure viral titer continue to improve and evolve. In this webinar, John Bechill (Principal Scientist, Analytics, Modalis Therapeutics), Peng Wang (Senior Scientist, Viral Vector Analytical Team Lead, Lonza) and Mark White (Associate Director of Biopharma and Translational Product Marketing, Bio-Rad), will discuss the need for accurate viral titer determination, traditional approaches to measuring viral titer, and the field’s trajectory into the future.
Recent advances in technology for viral titer measurement improve the accuracy and precision of these assays, overcoming persistent challenges and meeting the demands of the growing gene therapy landscape. These technological developments in determining viral purity and identity are key steps in fully realizing the potential of AAV- and lentiviral-mediated gene therapies.
Attend this webinar to discover: